Pharmacotherapy of intraocular pressure: Part I. Parasympathomimetic, sympathomimetic

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 16, 2009, Pages 2663-2677

  Costagliola, Ciro ^a   Dell'Omo, Roberto ^a   Romano, Mario R ^a   Rinaldi, Michele ^b   Zeppa, Lucia ^a   Parmeggiani, Francesco ^c  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Fixed combination; Glaucoma; Glaucoma medical treatment; Parasympathomimetics; Primary open angle glaucoma; Sympatholytics; Sympathomimetics

Indexed keywords

ACETYLCHOLINE; ADRENALIN; ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; APRACLONIDINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; CARBACHOL; CARTEOLOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DAPIPRAZOLE; DIPIVEFRINE; LATANOPROST; LEVOBUNOLOL; METIPRANOLOL; NORADRENALIN; PILOCARPINE; PLACEBO; TIMOLOL; TIMOLOL MALEATE;

ABNORMAL SENSATION; ABSENCE OF SIDE EFFECTS; ACCOMMODATION; ACETYLCHOLINE RELEASE; ALLERGIC CONJUNCTIVITIS; AQUEOUS HUMOR FLOW; AQUEOUS HUMOR FORMATION; ASTHMA; BLEPHAROCONJUNCTIVITIS; BLOOD PRESSURE; BRONCHOSPASM; BURNING SENSATION; CHEMICAL STRUCTURE; CHEMOSIS; CHOLESTEROL BLOOD LEVEL; CILIARY MUSCLE SPASM; CILIARY VASOCONSTRICTION; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONJUNCTIVA DISEASE; CONJUNCTIVA TOXICITY; CONJUNCTIVAL BLANCHING; CONJUNCTIVAL DEPOSIT; CONJUNCTIVITIS; CORNEA EPITHELIUM; CORNEA SENSIBILITY; DERMATITIS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRY NOSE; DYSLIPIDEMIA; DYSPNEA; EPIPHORA; EYE BURNING; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; EYE REDNESS; EYE STINGING; EYE SYNECHIA; EYE TOXICITY; EYELID DISEASE; EYELID EDEMA; FATIGUE; FOREIGN BODY REACTION; GASTROINTESTINAL CRAMP; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEART RATE; HUMAN; HYDROLYSIS; HYPEREMIA; HYPERHIDROSIS; HYPOTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; KERATITIS; LACRIMAL DUCT OCCLUSION; LACRIMATION; LIPOPROTEIN BLOOD LEVEL; LUNG EDEMA; LUNG FUNCTION; MIOSIS; MUSCLE CRAMP; MUSCLE SPASM; MYDRIASIS; NONHUMAN; NORMAL TENSION GLAUCOMA; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OPTIC NERVE LESION; PATIENT COMPLIANCE; PERIORBITAL DERMATITIS; PIGMENT GLAUCOMA; PIGMENTED CONJUNCTIVAL DEPOSITE; PSEUDOEXFOLIATION GLAUCOMA; PUPIL; RETINA MACULA EDEMA; REVIEW; SALIVATION; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN ALLERGY; SKIN MANIFESTATION; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TACHYPHYLAXIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; VASOCONSTRICTION; VISION; VISUAL ACUITY; VISUAL FIELD DEFECT; VOMITING; XEROSTOMIA;

HUMANS; INTRAOCULAR PRESSURE; PARASYMPATHOMIMETICS; SYMPATHOMIMETICS;

EID: 72949092044     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903300103     Document Type: Review

References (109)

1. Flanagan JG. Glaucoma update: epidemiology and new approaches to medical management. Ophthal Physiol Opt 1998;18:126-132
2. Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol 1983;118:166-191
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-267
4. European glaucoma society. Terminology and guidelines for glaucoma. Savona: Editrice Dogma; 2003
5. American Academy of Ophthalmology. Primary open-angle glaucoma, preferred practice pattern. San Francisco: American Academy of Ophthalmology; 2005
6. Costagliola C, Parmeggiani F, Sebastiani A. Assessing the cost-effectiveness of switching from a beta-blocker to latanoprost in the treatment of ocular hypertension. Expert Opin Pharmacother 2003;4:1775-1788
7. Shields MB, Ritch R, Krupin T. Classifications of the glaucomas. In: Ritch R, Shields MB, Krupin T, editors, the glaucomas: clinical science, 2nd edition. St. Louis, MO: Mosby; 1996. p. 717-725
8. Davson H. Physiology of the aqueous humor. In: Davson H, editor, physiology of the eye. London: Churchill Livingstone; 1980. p. 9-82
9. Phelps CD, Woodson RF, Kolker AE. Diurnal variation in intraocular pressure. Am J Ophthalmol 1974;77:367-377
10. Ericson LA. Twenty-four hourly variations of the aqueous flow. Examination with perilimbal suction cup. Acta Ophthalmol 1958;50:1-95
11. The AGIS investigators. The relationship between control of intraocular pressure and visual field deterioration. The AGIS investigators. Am J Ophthalmol 2000;130:429-440
12. Lichter PR, Musch DC, Gillespie BW, et al; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-1953
13. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-713
14. Heijl A, Leske MC, Bengtsson B, et al; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120: 1268-1279
15. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2008
16. Martínez A, Sánchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharmacol Ther 2009;25:239-248
17. Lachkar Y. Advantages of fixed combinations. J Fr Ophtalmol 2008;31:85-89
18. Duncan G, Collison DJ. Role of the non-neuronal cholinergic system in the eye: a review. Life Sci 2003;72:2013-2019
19. Von Weber A. Die ursache des glaukoms. Albr Graefes Arch Ophthalmol 1877;23:91-94
20. Sirbat D. Le Diamox® et la pilocarpine doivent-ils encore être prescrits? J Fr Ophtalmol 2007;30:72-73
21. Naveh-Floman N, Stahl V, Korczyn AD. Effect of pilocarpine on intraocular pressure in ocular hypertensive subjects. Ophthalmic Res 1986;18:34-37
22. Beasley H, Fraunfelder FT. Retinal detachments and topical ocular miotics. Ophthalmology 1979;86:95-98
23. Linnert D. Carbachol compared with pilocarpine in the therapy of glaucoma simplex. Klin Monatsbl Augenheilkd 1972;161:293-296
24. . Ellis PP. Systemic reactions to topical therapy. Int Ophthalmol Clin 1971;11:1-11
25. Krieglstein GK. Adrenergic therapy of glaucoma. Fortschr Ophthalmol 1988;85:125-129
26. Townsend DJ, Brubaker RF. Immediate effect of epinephrine on aqueous formation in the normal human eye as measured by fluorophotometry. Invest Ophthalmol Vis Sci 1980;19:256-266
27. Weekers R, Delmarcelle Y, Gustin J. Treatment of ocular hypertension by adrenalin and diverse sympathomimetic amines. Am J Ophthalmol 1955;40:666-672
28. Wang YL, Hayashi M, Yablonski ME, Toris CB. Effects of multiple dosing of epinephrine on aqueous humor dynamics in human eyes. J Ocul Pharmacol Ther 2002;18:53-63
29. Kerr CR, Hass I, Drance SM, et al. Cardiovascular effects of epinephrine and dipivalyl epinephrine applied topically to the eye in patients with glaucoma. Br J Ophthalmol 1982;66:109-114
30. Morgan TR, Mirate DJ, Bowman K, Green K. Topical epinephrine and regional ocular blood flow in aphakic eyes of rabbits. Arch Ophthalmol 1983;101:112-116
31. Domarus D. Adrenochrome deposits in the cornea ('Black cornea'). A clinical-pathological case report. Ophthalmologica 1977;175:166-170
32. AHFS Drug Information 2004. In: McEvoy GK, editor, Epinephrine (52:24 and 52:32). Bethesda, MD: American Society of Health-System Pharmacists; 2004. p.2712-2715, 2720-2
33. Neu F. Cystoid macular edema. Bull Soc Belge Ophtalmol 2007;304:71-76
34. Mills KB, Jacobs NA. A single-blind randomised trial comparing adrenaline 1.0% with dipivalyl epinephrine (propine) 0.1% in the treatment of open-angle glaucoma and ocular hypertension. Br J Ophthalmol 1988;72:465-468
35. Groh MJ, Michelson G, Harazny J, et al. Changes in retinal blood flow by topical administration of 0.1% dipivefrin. Ophthalmologe 1999;96:706-710
36. Costagliola C, Parmeggiani F, Ciancaglini M, et al. Ocular perfusion pressure and visual field indices modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients. Ophthalmologica 2003;217:39-44
37. Abrams DA, Robin AL, Pollack IP, et al. The safety and efficacy of topical 1% ALO/2145 (P-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol 1987;105:1205-1207
38. Stewart WC. Effect and side effects of apraclonidine. Klin Monatsbl Augenheilkd 1996;209:A7-13
39. Brubaker RF. Flow of aqueous humor in humans. Invest Ophthalm Vis Sci 1991;32:3145-3166
40. Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology 1995;102:456-461
41. Piletz JE, Halaris A, Saran A, Marler MR. Desipramine lowers tritiated para-aminoclonidine binding in platelets of depressed patients. Arch Gen Psychiatry 1991;48:813-820
42. Coleman AL, Robin AL, Pollak IP, et al. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch Ophthalmol 1990;108:1264-1267
43. De-mailly P. Bioavailability of antiglaucoma drugs. J Fr Ophtalmol 2000;23:518-522
44. Lin JC, Samuel F, Katz LJ, et al. The effect of topical glaucoma medications evaluated by perimetry. Br J Ophthalmol 2003;87:792
45. Threlkeld AB, Assalian AA, Allingham RR, Shields MB. Apraclonidine 0.5% versus 1% for controlling intraocular pressure elevation after argon laser trabeculoplasty. Ophthalmic Surg Lasers 1996;27:657-660
46. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41(Suppl 1):S9-18
47. Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol 2009;127:402-406
48. Loon SC, Liew G, Fung A, et al. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. Clin Experimental Ophthalmol 2008;36:281-289
49. Fudemberg SJ, Batiste C, Katz LJ. Efficacy, safety, and current applications of brimonidine. Expert Opin Drug Saf 2008;7:795-799
50. Craven ER, Walters TR, Williams R, et al; Combigan Study Group. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21:337-348
51. Thelen U, Buchholz P, Kimmich F. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany. Curr Med Res Opin 2009;25:1003-1009
52. Silvestrini B, Bonomi L, Lisciani R, et al. Effects of dapiprazole on pupillary size and intraocular pressure in rabbits. Arzneimittelforschung 1982;32:678-681
53. Bonomi L, Marchini G, Pagello P, et al. Effects of intraocular dapiprazole in the rabbit eye. J Cataract Refract Surg 1989;15:681-684
54. Warlich M, Weik R, Höh H, Ruprecht KW. Dapiprazol antagonizes tropicamide-and phenylephrine-induced mydriasis in the elderly. Ophthalmologe 1995;92:179-181
55. Bonomi L, Marchini G, Marraffa M, et al. Effects of the association of alpha and beta-blocking agents in glaucoma. J Ocul Pharmacol 1992;8:279-283
56. Mastropasqua L, Carpineto P, Ciancaglini M, et al. Effect of dapiprazole, an alpha-adrenergic blocking agent, on aqueous humor dynamics in pigmentary glaucoma. Ophthalmic Res 1996;28:312-318 (Pubitemid 26418285)
57. Zimmermann TJ, Kaufmann HE. Timolol: a beta adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1977;95:601-604
58. Obstbaum SA, Cioffi GA, Krieglstein GK, et al. Gold standard medical therapy for glaucoma: defining the criteria identifying measures for an evidence-based analysis. Clin Ther 2004;26:2102-2120
59. Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol 1993;9:373-384
60. Allen RC, Hertzmark E, Walker AM, Epstein DL. A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. Am J Ophthalmol 1986;15;101:535-541
61. Drance SM. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. J Glaucoma 1998;7:247-252
62. Turaçli ME, Ozden RG, Gürses MA. The effect of betaxolol on ocular blood flow and visual fields in patients with normotension glaucoma. Eur J Ophthalmol 1998;8:62-66
63. Osborne NN, Cazevieille C, Carvalho AL, et al. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res 1997;751:113-123
64. Stamper RL, Wigginton SA, Higginbotham EJ. Primary drug treatment for glaucoma: beta-blockers versus other medications. Surv Ophthalmol 2002;47:63-73
65. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. Br J Ophthalmol 2000;84:710-713
66. Yalvac IS, Basci NE, Dulger B, Duman S. Penetration of betaxolol HCL ionic suspension 0.25% and betaxolol HCL solution 0.50% into the aqueous humor. Eur J Ophthalmol 2007;17:368-371
67. Weinreb RN, Caldwell DR, Goode SM, Horwitz BL, et al. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution. Am J Ophthalmol 1990;110:189-192
68. Ros FE, Dake CL, Offerhaus L, Greve EL. Atenolol 4% eye drops and glaucoma. A double-blind short-term clinical trial of a new beta1-adrenergic blocking agent. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1977;205:61-70
69. Sterk CC. Atenolol 4% eyedrops in glaucoma simplex. Doc Ophthalmol 1980;48:309-314
70. Zhang WY, Po AL, Dua HS, et al. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2001;85:983-990
71. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006;47:2917-2923
72. Fuchsjäger-Mayrl G, Wally B, Rainer G, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 2005;89:1293-1297
73. Whitcup SM, Cantor LB, Vanderburgh AM, Chen K. A randomized doule masked multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma or ocular hypertension. Br J Ophthalmol 2003;87:57-62
74. Loon SC, Liew G, Fung A, et al. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. Clin Experiment Ophthalmol 2008;36:281-289
75. Nieminen T, Uusitalo H, Turjanmaa V, et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol 2005;61:369-374
76. Stewart WC. Timolol hemihydrate: a new formulation of timolol for the treatment of glaucoma. J Ocul Pharmacol Ther 1996;12:225-237
77. Dickstein K, Hapnes R, Aarsland T. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. Am J Ophthalmol 2001;132:626-632 (Pubitemid 33031278)
78. Mundorf TK, Ogawa T, Naka H, et al; US Istalol Study Group. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once daily and timolol maleate ophthalmic solution twice daily in the treatment of adults with glaucoma or ocular hypertension. Clin Ther 2004;26:541-551
79. Uusitalo H, Kähönen M, Ropo A, et al. Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma. Graefes Arch Clin Exp Ophthalmol 2006;244:1491-1496
80. Bron A, Velasque L, Rebica H, et al. Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost. J Fr Ophtalmol 2004;27:971-977
81. Gonzalez JP, Clissold SP. Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1987;34:648-661
82. Tang-Liu DD, Shackleton M, Richman JB. Ocular metabolism of levobunolol. J Ocul Pharmacol 1988;4:269-278
83. Woodward DF, Novack GD, Williams LS, et al. Dihydrolevobunolol is a potent ocular beta-adrenoceptor antagonist. J Ocul Pharmacol 1987;3:11-15
84. The Levobunolol Study Group. A beta-adrenoceptor antagonist effective in the long-term treatment of glaucoma. The Levobunolol Study Group (Appended). Ophthalmology 1985;92:1271-1276
85. Wandel T, Charap AD, Lewis RA, et al. Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol 1986;101:298-304 (Pubitemid 16132655)
86. Rakofsky SI, Lazar M, Almog Y, et al. Efficacy and safety of once-daily levobunolol for glaucoma therapy. Can J Ophthalmol 1989;24:2-6
87. Novack GD, Robin AL, Derick RJ. New medical treatments for glaucoma. Int Ophthalmol Clin 1993;33:183-202
88. Holdiness MR. Contact dermatitis to topical drugs for glaucoma. Am J Contact Dermatitis 2001;12:217-219
89. Ciancaglini M, Carpineto P, Agnifili L, et al. An in vivo confocal microscopy and impression cytology analysis of preserved and unpreserved levobunolol-induced conjunctival changes. Eur J Ophthalmol 2008;18:400-407
90. Mills KB, Wright G. A blind randomised cross-over trial comparing metipranolol 0.3% with timolol 0.25% in open-angle glaucoma: a pilot study. Br J Ophthalmol 1986;70:39-42
91. Battershill PE, Sorkin EM. Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 1988;36:601-615
92. De-mailly P, Lecherpie F. Metipranolol 0.1%: effect of a single dose on the nycthemeral pressure curve in an eye with chronic primary open-angle glaucoma. J Fr Ophtalmol 1987;10:447-449
93. Johns MD, Ponte CD. Acute pulmonary edema associated with ocular metipranolol use. Ann Pharmacother 1995;29:370-373
94. Akingbehin T, Villada JR. Metipranolol-associated granulomatous anterior uveitis. Br J Ophthalmol 1991;75:519-523
95. Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. Surv Ophthalmol 1998;42:557-570
96. Osborne NN, Wood JP. Metipranolol blunts nitric oxide-induced lipid peroxidation and death of retinal photoreceptors: a comparison with other anti-glaucoma drugs. Invest Ophthalmol Vis Sci 2004;45:3787-3795
97. Henness S, Swainston Harrison T, Keating GM. Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension. Drugs Aging 2007;24:509-528
98. Coleman AL, Diehl DL, Jampel HD, et al. Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch Ophthalmol 1990;108:1260-1263
99. Stewart WC, Cohen JS, Netland PA, et al. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Am J Ophthalmol 1997;124:498-505
100. Watson PG, Barnett MF, Parker V, Haybittle J. A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol 2001;85:962-968
101. De-mailly P, Allaire C, Trinquand C. Ocular hypotensive efficacy and safety of once daily carteolol alginate. Br J Ophthalmol 2001;85:921-924
102. Boland MV, Quigley HA. Risk factors and open angle glaucoma: classification and application. J Glaucoma 2007;16:406-418
103. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol 2008;53:S3-10
104. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-267
105. Singh K, Shrivastava A. Early aggressive intraocular pressure lowering, target intraocular pressure, and a novel concept for glaucoma care. Surv Ophthalmol 2008;53:S33-8
106. Strutton DR, Walt JG. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma 2004;13:221-226
107. Lütjen-Drecoll E, Wiendl H, Kaufman PL. Acute and chronic structural effects of pilocarpine on monkey outflow tissues. Trans Am Ophthalmol Soc 1998;96:171-191
108. American Academy of Ophthalmology. Preferred practice pattern for primary open-angle glaucoma. Chicago, IL: AAO; 2005
109. Sorensen SJ, Abel SR. Comparison of ocular beta-blockers. Ann Pharmacother 1996;30:43-54